Drug intelligence / Profile preview

CHF10073

Development stage: Phase 1
Lead developer: Chiesi
Modality: Small Molecules
Administration: Inhalation

Overview

CHF10073 is an investigational inhaled drug currently in Phase 1 clinical trials for the treatment of pulmonary fibrosis and related lung conditions. The drug is being developed by Chiesi Farmaceutici. Its safety, tolerability, and pharmacokinetics are being evaluated in healthy volunteers through single and multiple ascending dose studies. The precise mechanism of action has not been disclosed or remains unknown at this stage. CHF10073 is administered via inhalation, targeting lung tissue directly to potentially address fibrotic processes such as those seen in pulmonary fibrosis.

Beyond the preview

Go deeper on CHF10073.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHF10073.

Explore the full profile